Bromfenac Ophthalmic Solution 0.07 %: A Review of Its Use After Cataract Surgery

Abstract

The nonsteroidal anti-inflammatory drug bromfenac has recently been reformulated with a lower pH to facilitate a reduction in the concentration of bromfenac (to 0.07 %) while ensuring an ocular bioavailability similar to that of the 0.09 % formulation. Bromfenac ophthalmic solution 0.07 % (hereafter referred to as bromfenac 0.07 %) [Prolensa^®] is a once-daily topical ophthalmic solution available in the USA and Canada for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery. In an integrated analysis of two multicentre, phase III studies, bromfenac 0.07 % was significantly more effective than placebo in reducing ocular inflammation and pain. In these studies, bromfenac 0.07 % was well tolerated, with significantly lower incidences of adverse events, and adverse events affecting the study eye than with placebo. The most common adverse events in the study eye (eye pain, anterior chamber inflammation, foreign body sensation, photophobia, conjunctival hyperaemia and corneal oedema) occurred in numerically fewer bromfenac 0.07 % than placebo recipients. Thus, current evidence suggests once-daily bromfenac 0.07 % extends the treatment options currently available for the management of postoperative inflammation and pain following cataract surgery.